Abeona Therapeutics Stock Performance
| ABEO Stock | USD 5.08 0.19 3.61% |
On a scale of 0 to 100, Abeona Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 1.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abeona Therapeutics will likely underperform. Please check Abeona Therapeutics' potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Abeona Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Abeona Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Abeona Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.61) | Five Day Return 0.99 | Year To Date Return (4.33) | Ten Year Return (91.53) | All Time Return (100.00) |
Last Split Factor 1:25 | Last Split Date 2022-07-05 |
1 | Abeona Therapeutics GAAP EPS of -0.10 beats by 0.18 | 11/12/2025 |
2 | Can Abeona Therapeutics Inc. stock survive global slowdown - 2025 Trade Ideas Real-Time Chart Breakout Alerts - Newser | 12/04/2025 |
3 | Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas | 12/11/2025 |
4 | Why Abeona Therapeutics Inc. stock remains a top recommendation - Portfolio Update Report Verified Short-Term Plans - DonanmHaber | 12/19/2025 |
5 | Disposition of 25000 shares by Seshadri Vishwas of Abeona Therapeutics at 5.3096 subject to Rule 16b-3 | 12/29/2025 |
6 | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | 12/31/2025 |
7 | Trading Systems Reacting to Volatility - Stock Traders Daily | 01/05/2026 |
8 | Abeona Therapeutics Share Price Passes Above 50-Day Moving Average - Heres What Happened - MarketBeat | 01/16/2026 |
9 | Acquisition by Omalley Brendan M. of 113949 shares of Abeona Therapeutics subject to Rule 16b-3 | 01/20/2026 |
10 | Disposition of 13500 shares by Alvino Mark of Abeona Therapeutics at 5.2277 subject to Rule 16b-3 | 01/21/2026 |
11 | Disposition of 13578 shares by Omalley Brendan M. of Abeona Therapeutics at 5.3309 subject to Rule 16b-3 | 01/22/2026 |
12 | Acquisition by Alland Leila of 37313 shares of Abeona Therapeutics subject to Rule 16b-3 | 01/26/2026 |
13 | Movement Within Algorithmic Entry Frameworks - Stock Traders Daily | 01/27/2026 |
14 | Disposition of 6388 shares by Joseph Vazzano of Abeona Therapeutics at 5.89 subject to Rule 16b-3 | 02/04/2026 |
| Begin Period Cash Flow | 14.8 M | |
| Total Cashflows From Investing Activities | -39.2 M |
Abeona Therapeutics Relative Risk vs. Return Landscape
If you would invest 420.00 in Abeona Therapeutics on November 7, 2025 and sell it today you would earn a total of 88.00 from holding Abeona Therapeutics or generate 20.95% return on investment over 90 days. Abeona Therapeutics is currently generating 0.3974% in daily expected returns and assumes 4.0954% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Abeona, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Abeona Therapeutics Target Price Odds to finish over Current Price
The tendency of Abeona Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.08 | 90 days | 5.08 | about 38.31 |
Based on a normal probability distribution, the odds of Abeona Therapeutics to move above the current price in 90 days from now is about 38.31 (This Abeona Therapeutics probability density function shows the probability of Abeona Stock to fall within a particular range of prices over 90 days) .
Abeona Therapeutics Price Density |
| Price |
Predictive Modules for Abeona Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Abeona Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Abeona Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Abeona Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Abeona Therapeutics is not an exception. The market had few large corrections towards the Abeona Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Abeona Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Abeona Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.03 | |
β | Beta against Dow Jones | 1.91 | |
σ | Overall volatility | 0.37 | |
Ir | Information ratio | 0 |
Abeona Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Abeona Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Abeona Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Abeona Therapeutics had very high historical volatility over the last 90 days | |
| Abeona Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (63.73 M) with loss before overhead, payroll, taxes, and interest of (29.28 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (56.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 6388 shares by Joseph Vazzano of Abeona Therapeutics at 5.89 subject to Rule 16b-3 |
Abeona Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Abeona Stock often depends not only on the future outlook of the current and potential Abeona Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Abeona Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41 M | |
| Cash And Short Term Investments | 97.7 M |
Abeona Therapeutics Fundamentals Growth
Abeona Stock prices reflect investors' perceptions of the future prospects and financial health of Abeona Therapeutics, and Abeona Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abeona Stock performance.
| Return On Equity | 0.76 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | 205.88 % | ||||
| Operating Margin | (208.02) % | ||||
| Current Valuation | 96.62 M | ||||
| Shares Outstanding | 54.19 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 713.97 X | ||||
| Gross Profit | (29.28 M) | ||||
| EBITDA | (56.62 M) | ||||
| Net Income | (63.73 M) | ||||
| Cash And Equivalents | 20.1 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 23.05 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 3.27 X | ||||
| Cash Flow From Operations | (56.02 M) | ||||
| Earnings Per Share | 1.21 X | ||||
| Market Capitalization | 285.59 M | ||||
| Total Asset | 108.93 M | ||||
| Retained Earnings | (813.26 M) | ||||
| Working Capital | 84.27 M | ||||
| Current Asset | 31.95 M | ||||
| Current Liabilities | 6.51 M | ||||
About Abeona Therapeutics Performance
By examining Abeona Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Abeona Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Abeona Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 304.99 | 487.59 | |
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.63) | (0.66) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (1.30) | (1.37) |
Things to note about Abeona Therapeutics performance evaluation
Checking the ongoing alerts about Abeona Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abeona Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abeona Therapeutics had very high historical volatility over the last 90 days | |
| Abeona Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (63.73 M) with loss before overhead, payroll, taxes, and interest of (29.28 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (56.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 6388 shares by Joseph Vazzano of Abeona Therapeutics at 5.89 subject to Rule 16b-3 |
- Analyzing Abeona Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abeona Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Abeona Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abeona Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abeona Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abeona Therapeutics' stock. These opinions can provide insight into Abeona Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Will Biotechnology sector continue expanding? Could Abeona diversify its offerings? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Abeona Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 1.21 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Investors evaluate Abeona Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Abeona Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Abeona Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Abeona Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abeona Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Abeona Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.